Image Analysis Group (IAG), a leading global player in the realm of clinical trial imaging and artificial intelligence-driven biomarkers, has bolstered its presence in the United States by inaugurating a new office in Cambridge, Massachusetts. This strategic move places IAG at the heart of the Boston area’s vibrant life sciences community, enhancing its proximity to key biotechnology and pharmaceutical companies. The new location is poised to foster stronger partnerships and deliver localized support for clinical trials throughout the region.
The Cambridge office will play a crucial role in advancing IAG’s work across a diverse range of therapeutic disciplines, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By situating itself closer to sponsors and contract research organizations involved in Phase I-III clinical trials and imaging-intensive development programs, IAG aims to improve collaboration and efficiency. The expansion is also projected to create local job opportunities, with plans to hire in areas such as clinical imaging operations, data science, regulatory support, and business development within the next 12 to 24 months.
The new office will facilitate IAG’s comprehensive suite of imaging services, which encompass clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery. The company’s integration into the Boston life-sciences ecosystem is expected to enhance its collaborative efforts with biotechnology firms, pharmaceutical entities, academic institutions, and clinical research centers.
Globally, IAG supports clinical trials across North America, Europe, and the Asia-Pacific region, partnering with pharmaceutical, biotechnology, and medtech companies, as well as contract research organizations, in multi-center studies. The organization’s global operations are tailored to ensure standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across international trials.
Founded in 2007 and headquartered in London, Image Analysis Group (IAG) functions as an imaging Clinical Research Organization (iCRO), assisting pharmaceutical, biotechnology, and medical technology companies with imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, underpinning its operations across oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare disease indications.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.